MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: other"

  • 2023 International Congress

    Neuromyotonia in surgical scars: two case reports and review of literature.

    I. Amorín, J. Hackembruch, M. Nocera (Montevideo, Uruguay)

    Objective: Report and describe the clinic, neurophysiology and therapeutic response of two cases of neuromyotonia after a surgical wound, and review the literature on the…
  • 2023 International Congress

    A randomised, double blind, placebo controlled, crossover trial of incobotulinum toxin A treatment for upper limb tremor

    S. Nagaratnam, D. Wilson, H. Morales Briceno, V. Fung (Westmead, Australia)

    Objective: To assess the clinical and functional outcomes in patients with upper limb tremor with incobotulinum toxin A injections. Background: Upper limb tremor can be…
  • 2023 International Congress

    Is a Parkinson’s Sialorrhoea service effective?

    C. Williams, J. Adenwalla, B. Mohamed, C. Marquis, C. Thomas, R. Lewis-Morton (cardiff, United Kingdom)

    Objective: Evaluate the efficacy and tolerance of Botulinum Toxin A (BoNT A) in managing sialorrhoea in People with Parkinsons (PwP)Assess impact on quality of life…
  • 2023 International Congress

    Botulinum neurotoxin in FXTAS-related tremor: a “successful” case report

    AT. Cimmino, P. Sanginario, AR. Bentivoglio, P. Calabresi, M. Petracca, G. Di Lazzaro (Rome, Italy)

    Objective: We report the case of a man affected by FXTAS, presenting with disabling tremor who experienced a significant and long-lasting benefit from botulinum neurotoxin…
  • 2023 International Congress

    Development of a Vibro-Tactile Stimulation wristband for targeted therapy of Focal Task Specific Dystonias

    S. Arjun, A. Singh, H. Singh, R. Jain, I. Ahuja (Chandigarh, India)

    Objective: To design and develop a wristband that provides vibro-tactile stimulation as a sensory geste/trick for patients with FTSDs. The device will offer different frequencies…
  • 2022 International Congress

    Lack of immunogenicity of incobotulinumtoxinA in pediatrics: A pooled analysis

    F. Heinen, M. Banach, E. Dabrowski, D. Gaebler-Spira, H. Chambers, S. Schroeder, T. Geister, M. Althaus, A. Hanschmann, S. Berweck (Munich, Germany)

    Objective: To present pooled data analyses of the immunogenicity of incobotulinumtoxinA (INCO) in pediatrics. Background: BotulinumtoxinA (BoNT-A) is used to treat several chronic pediatric conditions,…
  • 2022 International Congress

    Can abdominal internal oblique muscle be a possible target for ultrasound-guided Botulinum toxin injection in patients with Parkinson’s Disease affected by axials problems? An ultrasound study of our case series.

    F. Marenco, P. Arcuri, M. Meloni, M. Ramella, A. Castagna (Milan, Italy)

    Objective: to demostrate the abdominal internal oblique muscle hypertrophy with ultrasound in patients with Parkinson’s Disease (PD) affected by axial problems, as a possible target…
  • 2022 International Congress

    ‘A study of seven patients with Hemimasticatory spasm; barriers to treatment and outcomes of botulinum toxin’

    A. Aundhakar, A. Nanavati, B. Mishal, P. Wadia (Mumbai, India)

    Objective: To assess barriers to treatment and outcomes of botulinum toxin in patients treated for Hemimasticatory spasm Background: Hemimasticatory spasm (HMS) is a rare peripherally induced…
  • 2022 International Congress

    IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson’s disease and other neurological conditions

    W. Jost, F. Pagan (Wolfach, Germany)

    Objective: To summarize clinical experience with incobotulinumtoxinA (INCO) for treating chronic sialorrhea due to Parkinson’s disease (PD), atypical parkinsonism, stroke, or traumatic brain injury in…
  • 2022 International Congress

    Successful treatment of Stiff Person Syndrome with botulinum toxin

    A. Gonçalves, F. Brunet, D. Ariton, O. de Fabregues (Loures, Portugal)

    Objective: Describe a case of Stiff Person Syndrome (SPS) treated with botulinum toxin injection and alert to the utility of botulinum toxin in this disorder.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley